首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Scientists said Thursday that a new AIDS vaccine, the first ever declared to protect a significant minority of humans against th
Scientists said Thursday that a new AIDS vaccine, the first ever declared to protect a significant minority of humans against th
admin
2011-06-24
54
问题
Scientists said Thursday that a new AIDS vaccine, the first ever declared to protect a significant minority of humans against the disease, would be studied to answer two fundamental questions: why it worked in some people but not in others, and why those infected despite vaccination got no benefit at all.
The vaccine—known as RV 144, a combination of two genetically engineered vaccines, neither of which had worked before in humans—was declared a qualified success after a six-year clinical trial on more than 16,000 volunteers in Thailand. Those who were vaccinated became infected at a rate nearly one-third lower than the others, the sponsors said Thursday morning.
"I don’t want to use a word like ’breakthrough,’ but I don’t think there’s any doubt that this is a very important result," said Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, which is one of the trial’s backers. "For more than 20 years now, vaccine trials have essentially been failures," Dr. Fauci said. "Now it’s like we were groping down an unlit path, and a door has been opened. We can start asking some very important questions."
It will still, however, take years of work before a vaccine that could end the epidemic, which has killed about 25 million people, can even be contemplated. "We often talk about whether a vaccine is even possible," said Mitchell Warren, the executive director of the AIDS Vaccine Advocacy Coalition, or AVAC. "This is not the vaccine mat ends the epidemic and says, ’O.K., let’s move on to something else.’ But it’s a fabulous new step that takes us in a new direction."
In which direction is still unknown. No one—including the researchers from the United States Army, the National Institutes of Health, the Thai Ministry of Public Health and two vaccine companies that tested the vaccine—knows why the vaccine gave even its weak indicator of success.
Experts generally disdain vaccines that do not protect at least 70 to 80 percent of those getting them. And this vaccine did not lower the viral loads of people who were vaccinated but caught the virus anyway, which was baffling because even mismatched vaccines usually do that. Simply repeating the trial to confirm the results would be pointless, experts agreed. The trial, the largest AIDS vaccine trial in history, cost $105 million and followed 16,402 Thai volunteers. The men and women ages 18 to 30 were recruited from two provinces southeast of the capital, Bangkok, from the general population rather than from high-risk groups like drug injectors or sex workers. Half got six doses of two different vaccines; half were given placebos. For ethical reasons, all were offered condoms, taught how to avoid infection and promised lifelong antiretroviral treatment if they got AIDS. They were then regularly tested for three years; 74 of those who got placebos became infected, but only 51 of those who got the vaccines did.
Although the difference was a mere 23 people, Col. Jerome H. Kim, a physician and the manager of the Army’s H.I.V. vaccine program, said it was statistically significant and meant that the vaccine was 31.2 percent effective. The results were surprising because both vaccines, one from the French company Sanofi-Aventis and one developed by Genentech but now licensed to Global Solutions for Infectious Diseases, a nonprofit health group, had failed when used individually. "This came out of the blue," said Chris Viehbacher, Sanofi’s chief executive. Even 31 percent protection "was at least twice as good as our own internal experts were predicting," he added. In 2004, there was so much skepticism about the trial just after it began that 22 top AIDS researchers published an editorial in Science magazine suggesting that it was a waste of money.
One conclusion from the surprising result, said Alan Bernstein, head of the Global HIV Vaccine Enterprise, an alliance of organizations pursuing a vaccine, "is that we’re not doing enough work in humans." Instead of going back to mice or monkeys, he said, different new variants on the two vaccines could be tried on a few hundred people in several countries. This vaccine was designed to combat the most common strain of the virus in Southeast Asia, so it would have to be modified for the strains circulating in Africa and the United States. Sanofi’s vaccine, Alvac-HIV, is a canarypox virus with three AIDS virus genes grafted onto it. Variations of it were tested in several countries; it was safe but not protective. The other vaccine, Aidsvax, was originally made by Genentech and contains a protein found on the surface of the AIDS virus; it is grown in a broth of hamster ovary cells. It was tested in Thai drug users in 2003 and in gay men in North America and Europe but failed. In 2007, two trials of a Merck vaccine in about 4,000 people were stopped early; it not only failed to work but for some men also seemed to increase the risk of infection.
Combining Alvac and Aidsvax was simply a hunch: if one was designed to create antibodies and the other to alert white blood cells, might they work together? One puzzling result—those who became infected had as much virus in their blood whether they got the vaccine or a placebo—suggests that RV 144 does not produce neutralizing antibodies, as most vaccines do, Dr. Fauci said. Antibodies are Y-shaped proteins formed by the body that clump onto invading viruses, blocking the surface spikes with which they attach to cells and flagging them for destruction. Instead, he theorized, it might produce "binding antibodies," which latch onto and empower effector cells, a type of white blood cell attacking the virus. Therefore, he said, it might make sense to screen all the stored Thai blood samples for binding antibodies. "The humbling prospect of this," he said, "is that we may not even be measuring the critical parameter. It may be something you don’t normally associate with protection." Dr. Lawrence Corey, the principal investigator for the HIV Vaccine Trials Network, who was not part of the RV 144 trial, said new work on weakened versions of the smallpox vaccine had produced better pox "spines" that could be substituted for the canarypox. New trials, he added, could be faster and smaller if they were done in African countries where AIDS is more common than in Thailand.
Which of the following is NOT true about RV 144?
选项
A、It has been on trial for six years.
B、People who get it are protected against AIDS.
C、People who get it are not as easily infected as others.
D、It is regarded as a very important finding in the history.
答案
B
解析
此题是事实题。由第一段可知,该疫苗只能保护一少部分人免受艾滋病的侵害。
转载请注明原文地址:https://kaotiyun.com/show/Y8YO777K
0
专业英语八级
相关试题推荐
Doyourememberallthoseyearswhenscientistsarguedthatsmokingwouldkillusbutthedoubtersinsistedthatwedidn’tknow
Cancunmeans"snakepit"inthelocalMayanlanguage,anditliveduptoitsnameasthehostofanimportantWorldTradeOrganiz
TwoofthemostimportantmeninAmericafacedeachotheratdawnonJuly1,1804.Therewerenowordsofgreetingnoranysmile
Oneofthemajorproblemsofnuclearenergyistheinabilityofscientiststodiscoverasafewaytodisposeoftheradioactive
InancientGreeceathleticfestivalswereveryimportantandhadstrongreligiousassociations.TheOlympianathleticfestivalh
Punditswhowanttosoundjudiciousarefondofwarningagainstgeneralizing.Eachcountryisdifferent,theysay,andnoonest
ErnestHemingwaywasoneofthe20thcentury’smostimportantwriters.Hissimple,directstylegreatlyinfluencedotherwriters
Inthepastfewyears,personalcomputers(PCs)havebecomebetter,strongerandfasterbutsohavethebitsandpiecesyouplug
HowtoConductEmploymentInterviewsGenerallyspeaking,thepurposeofemploymentinterviewsarethree-fold:a.tomatchac
随机试题
患者,男,40岁。患十二指肠溃疡,择期经上腹正中切口行胃大部切除术,并置切口内乳胶片引流。一般拔除引流片的时间是
A、过敏性紫癜肾炎B、IgA肾病C、急性链球菌感染后肾小球肾炎D、原发性小血管炎肾损害E、狼疮性肾炎患者,女性,23岁,发热、乏力、浮肿、尿少1个月,既往有光过敏史、时有关节肿痛,辅助检查显示中等量蛋白尿,镜下血尿,双侧胸
A、为治脾经湿热之口甜或口苦、多涎之要药B、为治湿阻寒凝之气滞胎动不安的是C、善治湿浊中阻证及阴寒闭暑证等,尤宜寒湿中阻之呕吐或兼表者D、为湿浊内停无论寒热虚实或有无表邪皆可用E、为治湿阻,食积,气滞所致的脘腹胀满
某地1998~2003年某家用电器销售量和人均年收入如表8-4所示,预计到2005年人均年收入较2003年增加36%,年人口增长控制在0.5%以内。 A、B两公司是该家用电器在国内市场的主要竞争对手,A公司为了制定主要针对B公司的竞争战略,运用竞争态
价值工程对象选择中,凭借开展价值工程活动人员的经验和智慧,根据对象选择应考虑的因素,通过定性分析选择对象的方法,称为()。
()是指银行通过合法筹集资金而自主发放的贷款。它的特点在于,银行负责收回本息,风险全部由银行自己承担。
根据《中华人民共和国全民所有制工业企业法》的规定,下列选项中,厂长可行使的职权有()。
下列海洋中哪一个是我国最大的海?()
新民主主义革命时期,党内犯“左”倾错误的人提出“毕其功于一役”的主张,搞所谓的“无间断”革命,这种错误倾向实质上是
DEVELOPMENTSINTHECONSTRUCTIONOFTALLBUILDINGS1Untilthenineteenthcentury,mosttallbuildingswereconstructedofloa
最新回复
(
0
)